scholarly journals Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model

2015 ◽  
pp. 1019 ◽  
Author(s):  
Jagat R. Kanwar ◽  
Kislay Roy ◽  
Rupinder Kanwar ◽  
Subramanian Krishnakumar ◽  
Chun Hei Antonio Cheung
Keyword(s):  
Colon Cancer ◽  
Recombinant Protein ◽  
Competitive Inhibition ◽  
Cancer Model

An Orthotopic Colon Cancer Model for Studying the B7-H3 Antitumor Effect In Vivo

2006 ◽  
Vol 10 (5) ◽  
pp. 635-645 ◽  
Author(s):  
C LUPU ◽  
C EISENBACH ◽  
M KUEFNER ◽  
J SCHMIDT ◽  
A LUPU ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Antitumor Effect ◽  
Cancer Model

Validation and field evaluation of a competitive inhibition ELISA based on the recombinant protein tSAG1 to detect anti-Neospora caninum antibodies in sheep and goats

2020 ◽  
Vol 284 ◽  
pp. 109201
Author(s):  
María Belén Novoa ◽  
Nerina Patricia Aguirre ◽  
Nadia Ormaechea ◽  
Sebastián Palmero ◽  
Lisandro Rouzic ◽  
...  
Keyword(s):  
Recombinant Protein ◽  
Competitive Inhibition ◽  
Neospora Caninum ◽  
Field Evaluation ◽  
Sheep And Goats ◽  
Inhibition Elisa

Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model

2015 ◽  
Vol 473 (1) ◽  
pp. 7-19 ◽  
Author(s):  
Tiangeng Dong ◽  
Tuo Yi ◽  
Mengxuan Yang ◽  
Shengli Lin ◽  
Wenxiang Li ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Tumour Cells ◽  
Toll Like Receptor ◽  
Cancer Model ◽  
Cancer Vaccination ◽  
Tlr9 Agonist ◽  
Broad Applicability ◽  
Human Cancers ◽  
Anti Cancer ◽  
Murine Colon

This is the first demonstration that α-galactosylceramide (α-Galcer)-loaded tumour cells (tumour–Gal) plus the Toll-like receptor 9 (TLR9) agonist as therapeutic anti-cancer vaccination. This strategy may have broad applicability and lead to development of effective immunotherapy against various human cancers.

Sign in / Sign up

Export Citation Format

Share Document